Norwegian cancer vaccine company Vaccibody has appointed Dr Martin Bonde as CEO, effective from August 10.
Bonde has over 25 years of international experience in the biotech industry, starting his career at Dako and going on to work at companies including Ostemeter, Visiopharm and Aros Pharma.
He joins from EpiTherapeutics, where he has held the role of CEO since 2009.
Tom Pike, chairman of Vaccibody, said: “We are delighted to welcome Martin Bonde to Vaccibody. The Vaccibody technology has a wide business development potential within many market segments, which will benefit greatly from Martin’s extensive track record in deal making.
“We also believe that our ability to attract an experienced industry executive with Martin’s credentials reflect positively on Vaccibody’s’ considerable potential”.
Bonde’s experience in the sector includes a number of transactions within business development, trade sales, mergers and acquisitions and management of research and development.